JP2022540678A5 - - Google Patents

Info

Publication number
JP2022540678A5
JP2022540678A5 JP2022502486A JP2022502486A JP2022540678A5 JP 2022540678 A5 JP2022540678 A5 JP 2022540678A5 JP 2022502486 A JP2022502486 A JP 2022502486A JP 2022502486 A JP2022502486 A JP 2022502486A JP 2022540678 A5 JP2022540678 A5 JP 2022540678A5
Authority
JP
Japan
Prior art keywords
polymorph
degrees
composition according
diffraction pattern
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540678A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/042028 external-priority patent/WO2021011586A1/en
Publication of JP2022540678A publication Critical patent/JP2022540678A/ja
Publication of JP2022540678A5 publication Critical patent/JP2022540678A5/ja
Priority to JP2025113468A priority Critical patent/JP2025148397A/ja
Pending legal-status Critical Current

Links

JP2022502486A 2019-07-16 2020-07-15 (r)-4-(1-((3-(ジフルオロメチル)-1-メチル-1h-ピラゾール-4-イル)スルホニル)-1-フルオロエチル)-n-(イソキサゾール-3-イル)ピペリジン-1-カルボキシアミドの多形体 Pending JP2022540678A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025113468A JP2025148397A (ja) 2019-07-16 2025-07-04 (r)-4-(1-((3-(ジフルオロメチル)-1-メチル-1h-ピラゾール-4-イル)スルホニル)-1-フルオロエチル)-n-(イソキサゾール-3-イル)ピペリジン-1-カルボキシアミドの多形体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874855P 2019-07-16 2019-07-16
US62/874,855 2019-07-16
PCT/US2020/042028 WO2021011586A1 (en) 2019-07-16 2020-07-15 Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025113468A Division JP2025148397A (ja) 2019-07-16 2025-07-04 (r)-4-(1-((3-(ジフルオロメチル)-1-メチル-1h-ピラゾール-4-イル)スルホニル)-1-フルオロエチル)-n-(イソキサゾール-3-イル)ピペリジン-1-カルボキシアミドの多形体

Publications (2)

Publication Number Publication Date
JP2022540678A JP2022540678A (ja) 2022-09-16
JP2022540678A5 true JP2022540678A5 (cg-RX-API-DMAC7.html) 2023-08-02

Family

ID=71895284

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022502486A Pending JP2022540678A (ja) 2019-07-16 2020-07-15 (r)-4-(1-((3-(ジフルオロメチル)-1-メチル-1h-ピラゾール-4-イル)スルホニル)-1-フルオロエチル)-n-(イソキサゾール-3-イル)ピペリジン-1-カルボキシアミドの多形体
JP2025113468A Pending JP2025148397A (ja) 2019-07-16 2025-07-04 (r)-4-(1-((3-(ジフルオロメチル)-1-メチル-1h-ピラゾール-4-イル)スルホニル)-1-フルオロエチル)-n-(イソキサゾール-3-イル)ピペリジン-1-カルボキシアミドの多形体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025113468A Pending JP2025148397A (ja) 2019-07-16 2025-07-04 (r)-4-(1-((3-(ジフルオロメチル)-1-メチル-1h-ピラゾール-4-イル)スルホニル)-1-フルオロエチル)-n-(イソキサゾール-3-イル)ピペリジン-1-カルボキシアミドの多形体

Country Status (15)

Country Link
US (3) US20210053939A1 (cg-RX-API-DMAC7.html)
EP (1) EP3999504A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022540678A (cg-RX-API-DMAC7.html)
KR (1) KR20220035176A (cg-RX-API-DMAC7.html)
CN (1) CN114127061A (cg-RX-API-DMAC7.html)
AU (1) AU2020315605B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022000474A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143965A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000050A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000117A2 (cg-RX-API-DMAC7.html)
IL (1) IL289817A (cg-RX-API-DMAC7.html)
MX (1) MX2022000606A (cg-RX-API-DMAC7.html)
PE (1) PE20220645A1 (cg-RX-API-DMAC7.html)
TW (1) TWI921306B (cg-RX-API-DMAC7.html)
WO (1) WO2021011586A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN117865941B (zh) * 2024-03-13 2024-06-28 上海方予健康医药科技有限公司 取代哌啶化合物及其制备方法和应用
WO2025244956A1 (en) 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
WO2005117882A2 (en) 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
WO2006074025A1 (en) 2004-12-30 2006-07-13 Janssen Pharmaceutica N.V. Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
EP1866285A1 (en) 2005-03-03 2007-12-19 F. Hoffmann-Roche AG 1-sulfonyl-piperdine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
WO2008120759A1 (ja) 2007-03-30 2008-10-09 Japan Tobacco Inc. ウレア化合物およびその用途
ES2442003T3 (es) 2007-06-20 2014-02-07 Mitsubishi Tanabe Pharma Corporation Nuevo derivado de sulfonamida de ácido malónico y uso farmacéutico del mismo
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
ES2499018T3 (es) 2007-09-20 2014-09-26 Irm Llc Compuestos y composiciones como moduladores de la actividad de GPR119
MX2010003621A (es) 2007-10-01 2010-04-14 Hoffmann La Roche N-heterociclil biaril carboxamidas como antagonistas del receptor ccr.
WO2009047161A1 (en) 2007-10-09 2009-04-16 F. Hoffmann-La Roche Ag Chiral cis-imidazolines
SG188117A1 (en) 2008-06-19 2013-03-28 Takeda Pharmaceutical Heterocyclic compound and use thereof
US8324178B2 (en) 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
JP5329646B2 (ja) 2009-04-01 2013-10-30 パナソニック株式会社 デジタル周波数/位相ロックドループ
WO2011059021A1 (ja) 2009-11-11 2011-05-19 大日本住友製薬株式会社 8-アザビシクロ[3.2.1]オクタン-8-カルボキサミド誘導体
WO2015005305A1 (ja) 2013-07-09 2015-01-15 小野薬品工業株式会社 Alxr作動化合物
HUE037134T2 (hu) 2013-08-07 2018-08-28 Merck Patent Gmbh Piperidin-karbamid-származékok
WO2015112806A2 (en) 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
SG11201705928XA (en) * 2015-01-22 2017-08-30 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
SG11202112723PA (en) 2019-05-19 2021-12-30 Myokardia Inc Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Similar Documents

Publication Publication Date Title
JP5159788B2 (ja) 1−(β−D−グルコピラノシル)−4−メチル−3−[5−(4−フルオロフェニル)−2−チエニルメチル]ベンゼン1/2水和物の結晶形
JP2022540668A5 (cg-RX-API-DMAC7.html)
JP2025176008A5 (cg-RX-API-DMAC7.html)
HRP20240713T1 (hr) Polimorfi od (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden- 1-il)-1-metil-1h-pirazol-4-karboksamida
JP2016106102A (ja) (3r,6r)−3−(2,3−ジヒドロ−1h−インデン−2−イル)−1−[(1r)−1−(2,6−ジメチル−3−ピリジニル)−2−(4−モルホリニル)−2−オキソエチル]−6−[(1s)−1−メチルプロピル]−2,5−ピペラジンジオンの新規結晶性形態
JP2025148397A5 (cg-RX-API-DMAC7.html)
JP2014074067A (ja) メシル酸イマチニブのf、g、h、iおよびk結晶形
CN103539795A (zh) 阿哌沙班的多晶型及其制备方法
HK1045155A1 (en) A crystalline form of celecoxib
JP2024095561A5 (cg-RX-API-DMAC7.html)
JP2022542803A5 (cg-RX-API-DMAC7.html)
JP2022523368A5 (cg-RX-API-DMAC7.html)
JP5160219B2 (ja) テルミサルタンの製造方法
JP2024547113A5 (cg-RX-API-DMAC7.html)
CN104098570A (zh) 替卡格雷晶型及其制备方法和用途
JP2024518429A5 (cg-RX-API-DMAC7.html)
JP2023530786A5 (cg-RX-API-DMAC7.html)
JP2023530785A5 (cg-RX-API-DMAC7.html)
JP2023517729A5 (cg-RX-API-DMAC7.html)
TW201427949A (zh) 塔適那偉(atazanavir)硫酸氫鹽之製法及其新穎的形式
CN107033094A (zh) 一种药物共晶的晶型及其制备方法和组合物
JP2024515770A5 (cg-RX-API-DMAC7.html)
CA3091642A1 (en) Agents and methods for treating dysproliferative diseases
JP2023523165A5 (cg-RX-API-DMAC7.html)
EP2155698A1 (en) Novel thermodynamically stable polymorphic form-l of letrozole